An uncertainty principle(UP),which offers information about a signal and its Fourier transform in the time-frequency plane,is particularly powerful in mathematics,physics and signal processing community.Under the pola...An uncertainty principle(UP),which offers information about a signal and its Fourier transform in the time-frequency plane,is particularly powerful in mathematics,physics and signal processing community.Under the polar coordinate form of quaternion-valued signals,the UP of the two-sided quaternion linear canonical transform(QLCT)is strengthened in terms of covariance.The condition giving rise to the equal relation of the derived result is obtained as well.The novel UP with covariance can be regarded as one in a tighter form related to the QLCT.It states that the product of spreads of a quaternion-valued signal in the spatial domain and the QLCT domain is bounded by a larger lower bound.展开更多
Objective:The aim of this study was to explore the difference of long-term prognosis of different treatment regimens in patients with stage ⅠB2, ⅡA2 cervical cancer. Methods:From August 1995 to September 2005, radic...Objective:The aim of this study was to explore the difference of long-term prognosis of different treatment regimens in patients with stage ⅠB2, ⅡA2 cervical cancer. Methods:From August 1995 to September 2005, radical hysterectomy was chosen as primary treatment regimen for 122 patients (group A), 85 patients underwent radical hysterectomy after effective neoadjuvant therapy (group B), and 98 patients received surgery after ineffective preoperative therapy (group C). All patients received postoperative therapy. Results:A total of 305 patients were analyzed. The maximum diameter of tumor was largest in group B, while the pathological risk factors (cervical infiltration, positive surgical margins) were in the lowest proportion. The 5-year mortality rate and relapse rate of group B were the highest, and the overall survival (OS) and progression-free survival (PFS) were the shortest (P < 0.05). No significant difference of long-term survival was found in group C and group A. No difference was found in the surgical of three groups. Large tumor more than 5.5 cm had higher effective ratio of treatment than those 5.5 cm or less. Patients received effective preoperative radiotherapy had better long-term prognosis than those received chemotherapy or radiochemotherapy. Conclusion:neoadjuvant treatment using for patients with ⅠB2, ⅡA2 cervical cancer is effective in reducing risk factors of pathological, but it could not improve the long-term survival. The indications of adjuvant therapy after surgery should be reconsidered. Those tumors of diameter 5.5 cm or less response poor to neoadjuvant treatment, and no improvement of survival was found, so direct surgical treatment is suggested for these patients. Radiotherapy is a better choice of preoperative treatment.展开更多
Background:The 21-gene recurrence score(RS)assay has been recommended by major guidelines for treatment decision in hormone receptor(HR)-positive early breast cancer(EBC).However,the genomic assay is not accessible an...Background:The 21-gene recurrence score(RS)assay has been recommended by major guidelines for treatment decision in hormone receptor(HR)-positive early breast cancer(EBC).However,the genomic assay is not accessible and affordable worldwide.Alternatively,an increasing number of studies have shown that traditional immunohistochemistry(IHC)can partially or even completely replace the role of the 21-gene genomic assay.Here,we developed and validated a predictive model(IHC3 model)combining the Ki-67 index,progesterone receptor(PR)expression,histologic grade,and tumor size to predict the recurrence risk of HR-positive EBC.Methods:The data from 389 patients(development set)with HR-positive,human epidermal growth factor receptor 2-negative,lymph node non-metastasized invasive breast cancer were used to construct the IHC3 model based on the Surexam®21-gene RS and the TAILORx clinical trial criteria.An additional 146 patients with the same characteristics constituted the validation set.The predictive accuracy of the IHC3 model was compared with that of Orucevic et al.’s nomogram.Invasive diseasefree survival(IDFS)was analyzed in the IHC3 predictive low-recurrence risk(pLR)group and the predictive high-recurrence risk(pHR)group.The Pearson chi-square test,Fisher exact test,and log-rank test were used for analysis.Results:The pLR and pHR group could be easily stratified using the decision tree model without network dependence.The accuracies of the IHC3 model were 86.1%in the development set and 87.7%in the validation set.The predictive accuracy of the IHC3 model and Orucevic et al.’s nomogram for the whole cohort was 86.5%and 86.9%,respectively.After a 52-month of median follow-up,a significant difference was found in IDFS between of the IHC3 pLR and the pHR groups(P=0.001)but not in the IDFS between the low-and high-recurrence risk groups according to the Surexam®21-gene RS and the TAILORx clinical trial criteria(P=0.556)or 21-gene binary RS group(P=0.511).Conclusions:The proposed IHC3 model could reliably predict low and high recurrence risks in most HR-positive EBC patients.This easy-to-use predictive model may be a reliable replacement for the 21-gene genomic assay in patients with EBC who have no access to or cannot afford the 21-gene genomic assay.展开更多
基金supported by Startup Foundation for Phd Research of Henan Normal University(No.5101119170155).
文摘An uncertainty principle(UP),which offers information about a signal and its Fourier transform in the time-frequency plane,is particularly powerful in mathematics,physics and signal processing community.Under the polar coordinate form of quaternion-valued signals,the UP of the two-sided quaternion linear canonical transform(QLCT)is strengthened in terms of covariance.The condition giving rise to the equal relation of the derived result is obtained as well.The novel UP with covariance can be regarded as one in a tighter form related to the QLCT.It states that the product of spreads of a quaternion-valued signal in the spatial domain and the QLCT domain is bounded by a larger lower bound.
文摘Objective:The aim of this study was to explore the difference of long-term prognosis of different treatment regimens in patients with stage ⅠB2, ⅡA2 cervical cancer. Methods:From August 1995 to September 2005, radical hysterectomy was chosen as primary treatment regimen for 122 patients (group A), 85 patients underwent radical hysterectomy after effective neoadjuvant therapy (group B), and 98 patients received surgery after ineffective preoperative therapy (group C). All patients received postoperative therapy. Results:A total of 305 patients were analyzed. The maximum diameter of tumor was largest in group B, while the pathological risk factors (cervical infiltration, positive surgical margins) were in the lowest proportion. The 5-year mortality rate and relapse rate of group B were the highest, and the overall survival (OS) and progression-free survival (PFS) were the shortest (P < 0.05). No significant difference of long-term survival was found in group C and group A. No difference was found in the surgical of three groups. Large tumor more than 5.5 cm had higher effective ratio of treatment than those 5.5 cm or less. Patients received effective preoperative radiotherapy had better long-term prognosis than those received chemotherapy or radiochemotherapy. Conclusion:neoadjuvant treatment using for patients with ⅠB2, ⅡA2 cervical cancer is effective in reducing risk factors of pathological, but it could not improve the long-term survival. The indications of adjuvant therapy after surgery should be reconsidered. Those tumors of diameter 5.5 cm or less response poor to neoadjuvant treatment, and no improvement of survival was found, so direct surgical treatment is suggested for these patients. Radiotherapy is a better choice of preoperative treatment.
基金This study was funded by the science and technology commission of Beijing:Optimization of breast cancer screening program for 35-75 years old women in Beijing(Grant No.D161100000816005)。
文摘Background:The 21-gene recurrence score(RS)assay has been recommended by major guidelines for treatment decision in hormone receptor(HR)-positive early breast cancer(EBC).However,the genomic assay is not accessible and affordable worldwide.Alternatively,an increasing number of studies have shown that traditional immunohistochemistry(IHC)can partially or even completely replace the role of the 21-gene genomic assay.Here,we developed and validated a predictive model(IHC3 model)combining the Ki-67 index,progesterone receptor(PR)expression,histologic grade,and tumor size to predict the recurrence risk of HR-positive EBC.Methods:The data from 389 patients(development set)with HR-positive,human epidermal growth factor receptor 2-negative,lymph node non-metastasized invasive breast cancer were used to construct the IHC3 model based on the Surexam®21-gene RS and the TAILORx clinical trial criteria.An additional 146 patients with the same characteristics constituted the validation set.The predictive accuracy of the IHC3 model was compared with that of Orucevic et al.’s nomogram.Invasive diseasefree survival(IDFS)was analyzed in the IHC3 predictive low-recurrence risk(pLR)group and the predictive high-recurrence risk(pHR)group.The Pearson chi-square test,Fisher exact test,and log-rank test were used for analysis.Results:The pLR and pHR group could be easily stratified using the decision tree model without network dependence.The accuracies of the IHC3 model were 86.1%in the development set and 87.7%in the validation set.The predictive accuracy of the IHC3 model and Orucevic et al.’s nomogram for the whole cohort was 86.5%and 86.9%,respectively.After a 52-month of median follow-up,a significant difference was found in IDFS between of the IHC3 pLR and the pHR groups(P=0.001)but not in the IDFS between the low-and high-recurrence risk groups according to the Surexam®21-gene RS and the TAILORx clinical trial criteria(P=0.556)or 21-gene binary RS group(P=0.511).Conclusions:The proposed IHC3 model could reliably predict low and high recurrence risks in most HR-positive EBC patients.This easy-to-use predictive model may be a reliable replacement for the 21-gene genomic assay in patients with EBC who have no access to or cannot afford the 21-gene genomic assay.
